甲状腺癌薬物療法のイロハ
Saved in:
| Published in | 日本耳鼻咽喉科免疫アレルギー感染症学会誌 Vol. 4; no. 1; pp. 37 - 42 |
|---|---|
| Main Authors | , |
| Format | Journal Article |
| Language | Japanese |
| Published |
日本耳鼻咽喉科免疫アレルギー感染症学会
2024
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 2435-7952 |
| DOI | 10.24805/jiaio.4.1_37 |
Cover
| Author | 岸田, 拓磨 岡野, 晋 |
|---|---|
| Author_xml | – sequence: 1 fullname: 岡野, 晋 organization: 国立がん研究センター東病院 – sequence: 1 fullname: 岸田, 拓磨 organization: 国立がん研究センター東病院 |
| BookMark | eNo9j71KA0EUhQdRMMaUvoHtrnNn7uwP2EjwDwI2Wg83Mze6S0xkN42lCRaKYKNCehtBLRQsfJ0FN49hULE4HL5TfHBWxOJgOGAh1kCGChNpNvKMsmGIIVgdL4iGQm2CODVqWbTKMutKI2MdgdQNsV7fvdXXH7PLz3p6M3t4rq-e6un46_2-unitxo_V5KWa3K6KpR71S279dVMc7WwftveCzsHufnurE-QKFQQ6Uh4TSL0h6Brvox6l4MEhS6c1IhADJYYwYQYnU0ZwkWJOKI3m6HVTbP5683JEx2zPiuyUinNLxShzfbY_tyxamEfH_7M7ocLmpL8BC-FYLg |
| ContentType | Journal Article |
| Copyright | 2024 日本耳鼻咽喉科免疫アレルギー感染症学会 |
| Copyright_xml | – notice: 2024 日本耳鼻咽喉科免疫アレルギー感染症学会 |
| DOI | 10.24805/jiaio.4.1_37 |
| DeliveryMethod | fulltext_linktorsrc |
| EISSN | 2435-7952 |
| EndPage | 42 |
| ExternalDocumentID | article_jiaio_4_1_4_37_article_char_ja |
| GroupedDBID | JSF RJT |
| ID | FETCH-LOGICAL-j2421-362d4819d5a1b5dd6fa91d1c4e0c33441ae1a85a48ee1c09e41c62ee8a96c09d3 |
| IngestDate | Wed Sep 03 06:31:26 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | false |
| IsScholarly | false |
| Issue | 1 |
| Language | Japanese |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-j2421-362d4819d5a1b5dd6fa91d1c4e0c33441ae1a85a48ee1c09e41c62ee8a96c09d3 |
| OpenAccessLink | https://www.jstage.jst.go.jp/article/jiaio/4/1/4_37/_article/-char/ja |
| PageCount | 6 |
| ParticipantIDs | jstage_primary_article_jiaio_4_1_4_37_article_char_ja |
| PublicationCentury | 2000 |
| PublicationDate | 20240000 |
| PublicationDateYYYYMMDD | 2024-01-01 |
| PublicationDate_xml | – year: 2024 text: 20240000 |
| PublicationDecade | 2020 |
| PublicationTitle | 日本耳鼻咽喉科免疫アレルギー感染症学会誌 |
| PublicationTitleAlternate | 耳鼻免疫アレルギー感染症 |
| PublicationYear | 2024 |
| Publisher | 日本耳鼻咽喉科免疫アレルギー感染症学会 |
| Publisher_xml | – name: 日本耳鼻咽喉科免疫アレルギー感染症学会 |
| References | 2)国立がん研究センター：がん種別統計情報 甲状腺．がん情報サービス がん統計，http://ganjoho.jp/reg_stat/statistics/stat/cancer/24_thyroid.html，参照（2023/10/31） 16)Cancer Genome Atlas Research Network: Integrated genomic characterization of papillary thyroid carcinoma. Cell 2014; 159: 676–690. 7)Takahashi S, Kiyota N, Yamazaki T, et al.: A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer. Future Oncol 2019; 15: 717–726. 6)Ito Y, Onoda N, Ito KI, et al.: Sorafenib in Japanese patients with locally advanced or metastatic medullary thyroid carcinoma and anaplastic thyroid carcinoma. Thyroid 2017; 27: 1142–1148. 22)Falchock GS, Millward M, Hong D, et al.: BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer. Thyroid 2015; 25: 71–77. 13)Elisei R, Schlumberger MJ, Muller SP, et al.: Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol 2013; 31: 3639–3646. 8)Higashiyama T, Sugino K, Hara H, et al.: Phase II study of the efficacy and safety of Lenvatinib for anaplastic thyroid cancer (HOPE). Eur J Cancer 2022; 173: 210–218. 20)Garcia-Foncrillas J, Bokemeyer C, Italiano A, et al.: Indirect treatment comparison of larotrectinib versus entrectinib on treating patients with TRK gene fusion cancers. Cancers 2022; 14: 1793. 19)Weguespack S G, Drilon A, Lin JJ, et al.: Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma. European Journal of Endocrinology 2022; 186: 631–643. 1)Zehir A, Benayed R, Shah RH, et al.: Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med 2017; 23: 703–713. 26)Wang JR, Zafereo ME, Dadu R, et al.: Complete surgical resection following neoadjuvant dabrafenib plus trametinib in BRAF(V600E)-mutated anaplastic thyroid carcinoma. Thyroid 2019; 29: 1036–1043. 9)Kiyota N, Schlumberger M, Muro K, et al.: Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine-refractory differentiated thyroid cancer. Cancer Sci 2015; 106: 1714–1721. 15)Elisei R, Tacito A, Ramone T, et al.: Twenty-five years experience on RET genetic screening on hereditary MTC: an update on the prevalence of germline RET mutations. Genes [Internet] 2019: 10; 10. http://dx.doi.org/10.3390/genes10090698，参照（2023/10/31） 17)Hadoux J, Elisei R, Marcia SB, et al.: Phase 3 trial of selpercatinib in advanced RET-mutant medullary thyroid cancer. N Engl J Med 2023; 389: 1851–1861. 18)Doebele RC, Drilon A, Paz -Ares, et al.: Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumors: integrated analysis of three phase 1–2 trials. Lancet Oncol 2020; 21: 271–282. 12)Uchino K, Komoda M, Tomomatsu J, et al.: Safety and tolerability of vandetanib in Japanese patients with medullary thyroid cancer: a phase I/II open-label study. Endocr Pract 2017; 23: 149–156. 24)Subbiah V, Kreitman RJ, Wainberg ZA, et al.: Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600E-mutant anaplastic thyroid cancer. J Clin Oncol 2018; 36: 7–13. 10)Tahara M, Takami H, Ito Y, et al.: Planned drug holiday in a cohort study exploring the effect of lenvatinib on differentiated thyroid cancer. J Clin Oncol 2021; 39(15_suppl): 6070. 25)Subbiah V, Kreitman RJ, Wainberg ZA, et al.: Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study. Annals of Oncology 2022; 33: 406–415. 3)Wells SA Jr, Robinson BG, Gagel RF, et al.: Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 2012; 30: 134–141. 5)Schlumberger M, Tahara M, Wirth LJ, et al.: Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 2015; 372: 621–630. 30)Prior IA, Hood FE, Hartley JL: The frequency of ras mutations in cancer. Cancer Res 2020; 80: 2969–2974. 23)Shah MH, Wei L, Wirth LJ, et al.: Results of randomized phase II trial of dabrafenib versus dabrafenib plus trametinib in BRAF V600-mutated papillary thyroid carcinoma. Journal of Clinical Oncology 2017; 35: 6022–6022. 4)Brose MS, Nutting CM, Jarzab B, et al.: Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomized, double-blind, phase 3 trial. Lancet 2014; 384: 319–328. 21)Marabelle A, Fakih M, Lopez J, et al.: Association of tumor mutation burden with outcomes in patients with advanced solid tumors treated with pembrolizumab: prospective biomarker analysis of the multicohort, open label, phase 2 KEYNOTE-158 study. The Lancet Oncology 2020; 21: 1353–1365. 11)Matsuyama C, Enokida T, Ueda Y, et al.: Planned drug holidays during treatment with lenvatinib for radioiodine-refractory differentiated thyroid cancer: a retrospective study. Front Oncol 2023; 13: 1139659. 14)Wirth LJ, Sherman E, Robinson B, et al.: Efficacy of selpercatinib in RET-altered thyroid cancers. N Engl J Med 2020; 383: 825–835. 27)Kelly LM, Barila G, Liu P, et al.: Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer. Proc Natl Acad Sci U S A 2014; 111: 4233–4238. 28)Godbert Y, Henriques de Figueiredo B, Bonichon F, et al.: Remarkable response to crizotinib in woman with anaplastic lymphoma kinase-rearranged anaplastic thyroid carcinoma. J Clin Oncol 2015; 33: e84–e87. 29)Gambacotri-Passerini C, Orlov S, Zhang L, et al.: Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study. Am J Hematol 2018; 93: 607–614. |
| References_xml | – reference: 25)Subbiah V, Kreitman RJ, Wainberg ZA, et al.: Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study. Annals of Oncology 2022; 33: 406–415. – reference: 11)Matsuyama C, Enokida T, Ueda Y, et al.: Planned drug holidays during treatment with lenvatinib for radioiodine-refractory differentiated thyroid cancer: a retrospective study. Front Oncol 2023; 13: 1139659. – reference: 21)Marabelle A, Fakih M, Lopez J, et al.: Association of tumor mutation burden with outcomes in patients with advanced solid tumors treated with pembrolizumab: prospective biomarker analysis of the multicohort, open label, phase 2 KEYNOTE-158 study. The Lancet Oncology 2020; 21: 1353–1365. – reference: 8)Higashiyama T, Sugino K, Hara H, et al.: Phase II study of the efficacy and safety of Lenvatinib for anaplastic thyroid cancer (HOPE). Eur J Cancer 2022; 173: 210–218. – reference: 15)Elisei R, Tacito A, Ramone T, et al.: Twenty-five years experience on RET genetic screening on hereditary MTC: an update on the prevalence of germline RET mutations. Genes [Internet] 2019: 10; 10. http://dx.doi.org/10.3390/genes10090698，参照（2023/10/31） – reference: 6)Ito Y, Onoda N, Ito KI, et al.: Sorafenib in Japanese patients with locally advanced or metastatic medullary thyroid carcinoma and anaplastic thyroid carcinoma. Thyroid 2017; 27: 1142–1148. – reference: 12)Uchino K, Komoda M, Tomomatsu J, et al.: Safety and tolerability of vandetanib in Japanese patients with medullary thyroid cancer: a phase I/II open-label study. Endocr Pract 2017; 23: 149–156. – reference: 13)Elisei R, Schlumberger MJ, Muller SP, et al.: Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol 2013; 31: 3639–3646. – reference: 24)Subbiah V, Kreitman RJ, Wainberg ZA, et al.: Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600E-mutant anaplastic thyroid cancer. J Clin Oncol 2018; 36: 7–13. – reference: 23)Shah MH, Wei L, Wirth LJ, et al.: Results of randomized phase II trial of dabrafenib versus dabrafenib plus trametinib in BRAF V600-mutated papillary thyroid carcinoma. Journal of Clinical Oncology 2017; 35: 6022–6022. – reference: 1)Zehir A, Benayed R, Shah RH, et al.: Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med 2017; 23: 703–713. – reference: 22)Falchock GS, Millward M, Hong D, et al.: BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer. Thyroid 2015; 25: 71–77. – reference: 16)Cancer Genome Atlas Research Network: Integrated genomic characterization of papillary thyroid carcinoma. Cell 2014; 159: 676–690. – reference: 4)Brose MS, Nutting CM, Jarzab B, et al.: Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomized, double-blind, phase 3 trial. Lancet 2014; 384: 319–328. – reference: 10)Tahara M, Takami H, Ito Y, et al.: Planned drug holiday in a cohort study exploring the effect of lenvatinib on differentiated thyroid cancer. J Clin Oncol 2021; 39(15_suppl): 6070. – reference: 3)Wells SA Jr, Robinson BG, Gagel RF, et al.: Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 2012; 30: 134–141. – reference: 29)Gambacotri-Passerini C, Orlov S, Zhang L, et al.: Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study. Am J Hematol 2018; 93: 607–614. – reference: 14)Wirth LJ, Sherman E, Robinson B, et al.: Efficacy of selpercatinib in RET-altered thyroid cancers. N Engl J Med 2020; 383: 825–835. – reference: 9)Kiyota N, Schlumberger M, Muro K, et al.: Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine-refractory differentiated thyroid cancer. Cancer Sci 2015; 106: 1714–1721. – reference: 18)Doebele RC, Drilon A, Paz -Ares, et al.: Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumors: integrated analysis of three phase 1–2 trials. Lancet Oncol 2020; 21: 271–282. – reference: 19)Weguespack S G, Drilon A, Lin JJ, et al.: Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma. European Journal of Endocrinology 2022; 186: 631–643. – reference: 30)Prior IA, Hood FE, Hartley JL: The frequency of ras mutations in cancer. Cancer Res 2020; 80: 2969–2974. – reference: 27)Kelly LM, Barila G, Liu P, et al.: Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer. Proc Natl Acad Sci U S A 2014; 111: 4233–4238. – reference: 20)Garcia-Foncrillas J, Bokemeyer C, Italiano A, et al.: Indirect treatment comparison of larotrectinib versus entrectinib on treating patients with TRK gene fusion cancers. Cancers 2022; 14: 1793. – reference: 5)Schlumberger M, Tahara M, Wirth LJ, et al.: Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 2015; 372: 621–630. – reference: 2)国立がん研究センター：がん種別統計情報 甲状腺．がん情報サービス がん統計，http://ganjoho.jp/reg_stat/statistics/stat/cancer/24_thyroid.html，参照（2023/10/31） – reference: 7)Takahashi S, Kiyota N, Yamazaki T, et al.: A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer. Future Oncol 2019; 15: 717–726. – reference: 26)Wang JR, Zafereo ME, Dadu R, et al.: Complete surgical resection following neoadjuvant dabrafenib plus trametinib in BRAF(V600E)-mutated anaplastic thyroid carcinoma. Thyroid 2019; 29: 1036–1043. – reference: 17)Hadoux J, Elisei R, Marcia SB, et al.: Phase 3 trial of selpercatinib in advanced RET-mutant medullary thyroid cancer. N Engl J Med 2023; 389: 1851–1861. – reference: 28)Godbert Y, Henriques de Figueiredo B, Bonichon F, et al.: Remarkable response to crizotinib in woman with anaplastic lymphoma kinase-rearranged anaplastic thyroid carcinoma. J Clin Oncol 2015; 33: e84–e87. |
| SSID | ssib050736103 ssib045268852 ssj0003322029 |
| Score | 1.9620919 |
| SourceID | jstage |
| SourceType | Publisher |
| StartPage | 37 |
| SubjectTerms | BRAF がんゲノム医療 がん薬物療法 チロシンキナーゼ阻害薬 甲状腺癌 |
| Title | 甲状腺癌薬物療法のイロハ |
| URI | https://www.jstage.jst.go.jp/article/jiaio/4/1/4_37/_article/-char/ja |
| Volume | 4 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | 日本耳鼻咽喉科免疫アレルギー感染症学会誌, 2024, Vol.4(1), pp.37-42 |
| journalDatabaseRights | – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources databaseCode: M~E dateStart: 20210101 customDbUrl: isFulltext: true eissn: 2435-7952 dateEnd: 99991231 titleUrlDefault: https://road.issn.org omitProxy: true ssIdentifier: ssib050736103 providerName: ISSN International Centre |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1R27bhQxcBVCQ4NAgHgrRabcY_3as0t7b08RElSJlG61uzZSrkgQujQpkEhEkQiJBpDS0yABBUgUiL85ictnMPbuHneBIqSjuNV4bM_MznjPY2s8jqLV2gpVOZrGlQ_24xW3cemoi61jSZ2yspIhu_6jx-naBn-4KTaXLvyYi1raHVe9eu-v50rOY1XEoV39Kdl_sOyMKCIQRvviEy2MzzPZGPI-KA6GekBqMCnkEqQAo0OVApl5jEpBZ6GNAq26KuyVgmGgBOQMPUrQeQAoaB4ABnrQAnIh_M93VH3QIgBZIC59zARSyxWYDIyBXICiYAYBSD1r5KuRNfEYFFIOgiQom-n40o5v1gGzqrzFIHFkKjmoYeA-BMUCHXy7vqeMMmvUA_ctlfaCaY166EaWb4IK08RLij1kCAcNpLBsTjUzstNx0jWTpuWoUTw5v2tCf--X_kcaaqboMBdQHjKLioWJi__xfTaTUJNFp3VnmtxlpydKymXik4qMtsqtnR7vkaLrtJB7vB3ZRWhW8ILgj_WLDu0PBhYjXJ1cpH43zAfOPs-7f3N_d71sTuaHMi48GPrqbLYDynAuSahqEt8GgR7Mi4Mu4QgXSF1wZfD31q9El9uF2opuhLgaLY3Ka9Hq9M2X6dG3k5ffp8evTt59nB5-mB7v__z6dvLi82T__eTg0-Tg9fVoY5ivZ2txe89IPPIBETH6cJajZ2xFSSphbfqkVMSSmrukZgzXC6UjpRQll86ROlGOkzqlzslSpVi07Ea0vL2z7W5GKz5joL9hQRFZcVy5q1pWtuoTJ8qaW57cikTzUsXTJplMcTYV3z5nvzvRJT_6mz3Du9Hy-Nmuu4de9Li6H4z1C8rck10 |
| linkProvider | ISSN International Centre |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=%E7%94%B2%E7%8A%B6%E8%85%BA%E7%99%8C%E8%96%AC%E7%89%A9%E7%99%82%E6%B3%95%E3%81%AE%E3%82%A4%E3%83%AD%E3%83%8F&rft.jtitle=%E6%97%A5%E6%9C%AC%E8%80%B3%E9%BC%BB%E5%92%BD%E5%96%89%E7%A7%91%E5%85%8D%E7%96%AB%E3%82%A2%E3%83%AC%E3%83%AB%E3%82%AE%E3%83%BC%E6%84%9F%E6%9F%93%E7%97%87%E5%AD%A6%E4%BC%9A%E8%AA%8C&rft.au=%E5%B2%A1%E9%87%8E%2C+%E6%99%8B&rft.au=%E5%B2%B8%E7%94%B0%2C+%E6%8B%93%E7%A3%A8&rft.date=2024&rft.pub=%E6%97%A5%E6%9C%AC%E8%80%B3%E9%BC%BB%E5%92%BD%E5%96%89%E7%A7%91%E5%85%8D%E7%96%AB%E3%82%A2%E3%83%AC%E3%83%AB%E3%82%AE%E3%83%BC%E6%84%9F%E6%9F%93%E7%97%87%E5%AD%A6%E4%BC%9A&rft.eissn=2435-7952&rft.volume=4&rft.issue=1&rft.spage=37&rft.epage=42&rft_id=info:doi/10.24805%2Fjiaio.4.1_37&rft.externalDocID=article_jiaio_4_1_4_37_article_char_ja |